Theratechnologies (TSE:TH) Share Price Crosses Above 50 Day Moving Average of $1.77

Theratechnologies Inc. (TSE:THGet Free Report) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$1.77 and traded as high as C$2.25. Theratechnologies shares last traded at C$1.92, with a volume of 69,910 shares trading hands.

Theratechnologies Stock Down 10.3 %

The firm has a market capitalization of C$88.28 million, a price-to-earnings ratio of -2.43, a price-to-earnings-growth ratio of -8.50 and a beta of 1.81. The company has a current ratio of 1.15, a quick ratio of 0.64 and a debt-to-equity ratio of 562.07. The firm has a 50 day moving average price of C$1.77 and a two-hundred day moving average price of C$2.01.

Theratechnologies (TSE:THGet Free Report) last released its quarterly earnings results on Wednesday, April 10th. The company reported C($0.13) earnings per share for the quarter. The company had revenue of C$21.85 million during the quarter. Theratechnologies had a negative return on equity of 1,116.86% and a negative net margin of 23.04%. On average, equities analysts expect that Theratechnologies Inc. will post 0.0320362 earnings per share for the current fiscal year.

Theratechnologies Company Profile

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

Read More

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.